Big-hitting trio join Bicycle Therapeutics’ Clinical Advisory Board
Bicycle CEO Kevin Lee said: “Each of them has dedicated their careers to advancing the care of patients with cancer through the development of novel therapeutics.
“Their expertise will provide invaluable guidance and insights for the global development of our clinical oncology programs as we work to develop our precision-targeted therapies for the benefit of patients around the world.”
Burris serves as president and chief medical officer of Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organisations conducting community-based clinical trials.
At SCRI, he has focused on the development of new cancer agents with an emphasis on first-in-human therapies, having led the trials of many novel antibodies, small molecules and chemotherapies that are now approved by the FDA and have changed the standard of care for several types of cancers.
Eckstein is a board-certified senior consultant pathologist at the University Hospital Erlangen (FAU Erlangen-Nürnberg). His clinical interests are centered around genitourinary pathology, immunopathology and predictive molecular pathology.
Dr. Eckstein leads a translational research group focusing on systems immunology in cancer and deciphering the targetable surface proteome for future drug development of antigen-specific drug conjugates.
Niklas Klümper is a senior consultant for Urology & Genitourinary Oncology at the University Hospital Bonn, where he leads a translational uro-oncology research group focusing on advancing precision oncology.
His specific interests include the development of drug conjugates, with a broader goal of tailoring treatments to the unique molecular profiles and disease characteristics of patients.
Bicycle Therapeutics is a clinical-stage pharma company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics.
The company is also developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.